Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.19
- Piotroski Score 3.00
- Grade Buy
- Symbol (VIR)
- Company Vir Biotechnology, Inc.
- Price $7.75
- Changes Percentage (5.66%)
- Change $0.42
- Day Low $7.39
- Day High $7.75
- Year High $13.09
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/31/2024
- Fiscal Year End N/A
- Average Stock Price Target $28.19
- High Stock Price Target $35.00
- Low Stock Price Target $15.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$4.01
- Trailing P/E Ratio -2.8
- Forward P/E Ratio -2.8
- P/E Growth -2.8
- Net Income $-615,061,000
Income Statement
Quarterly
Annual
Latest News of VIR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Sweden's Environmental Minister Reiterates No Bail Out For Northvolt
Romina Pourmokhtari, Sweden's youngest minister at 25, oversees Climate and Enterprise. Facing criticism for climate policy, she emphasizes private capital over public funding for projects like Northv...
By Forbes | 9 hours ago -
Businesses say Australia's economy depends on the environment. Will Labor's 'nature-positive' summit help?
Financial leaders urge focus on protecting and restoring nature in Australia ahead of a global summit. While details are scarce, calls for nature conservation and restoration are emphasized due to the...
By The Guardian | 17 hours ago -
Ex- Virginia cop who killed shoplifting suspect acquitted of manslaughter, guilty on firearm charge
A former police officer in Virginia was acquitted of involuntary manslaughter for fatally shooting a shoplifting suspect. However, he was convicted of reckless handling of a firearm. The officer claim...
By AP NEWS | 19 hours ago
